Stock DNA
Pharmaceuticals & Biotechnology
PKR 103,392 Million (Large Cap)
18.00
NA
0.95%
-0.31
23.46%
3.65
Revenue and Profits:
Net Sales:
17,346 Million
(Quarterly Results - Mar 2025)
Net Profit:
1,600 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.96%
0%
-5.96%
6 Months
-11.4%
0%
-11.4%
1 Year
44.14%
0%
44.14%
2 Years
153.13%
0%
153.13%
3 Years
48.52%
0%
48.52%
4 Years
27.69%
0%
27.69%
5 Years
69.59%
0%
69.59%
Abbott Laboratories (Pakistan) Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.90%
EBIT Growth (5y)
16.47%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
2.91
Tax Ratio
45.92%
Dividend Payout Ratio
18.70%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
73.44%
ROE (avg)
21.43%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
4.43
EV to EBIT
9.71
EV to EBITDA
8.35
EV to Capital Employed
5.69
EV to Sales
1.52
PEG Ratio
0.16
Dividend Yield
0.84%
ROCE (Latest)
58.62%
ROE (Latest)
25.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
17,346.50
18,613.10
-6.80%
Operating Profit (PBDIT) excl Other Income
2,973.90
3,277.90
-9.27%
Interest
3.90
5.00
-22.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
1,599.70
1,285.00
24.49%
Operating Profit Margin (Excl OI)
145.60%
151.80%
-0.62%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -6.80% vs 7.19% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is 24.49% vs -28.97% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
68,177.20
55,475.30
22.90%
Operating Profit (PBDIT) excl Other Income
10,134.30
3,528.90
187.18%
Interest
23.60
30.30
-22.11%
Exceptional Items
0.00
500.10
-100.00%
Consolidate Net Profit
5,234.20
261.80
1,899.31%
Operating Profit Margin (Excl OI)
122.50%
35.10%
8.74%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 22.90% vs 12.62% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 1,899.31% vs -91.29% in Dec 2023
About Abbott Laboratories (Pakistan) Ltd. 
Abbott Laboratories (Pakistan) Ltd.
Pharmaceuticals & Biotechnology
Abbott Laboratories (Pakistan) Limited is a Pakistan-based healthcare company. The Company is engaged in the manufacture, import and marketing of research-based pharmaceutical, nutritional, diagnostic, diabetic care, hospital and consumer products. The Company's segments include Pharmaceutical, Nutritional and Others. The Pharmaceutical segment is engaged in the manufacture, import and marketing of research-based pharmaceutical products registered with the Drug Regulatory Authority of Pakistan. The Nutritional segment is engaged in the import and marketing of pediatric nutritional products and medical nutritional products. The Others segment represents the manufacture, import and marketing of diagnostic equipment, diabetes care, molecular devices, their testing kits and general healthcare products. The Company has its presence in various therapeutic areas, including gastroenterology, pain, respiratory, cardio vascular and metabolic, and women's and men's health, among others.
Company Coordinates 
Company Details
Opposite Radio Pakistan Transmission Hyderabad Road, Landhi. KARACHI None : 75120
Registrar Details






